^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Ovarian Cancer
    Drug:Aybintio (bevacizumab biosimilar) (VEGF-A inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A1 - Approval
    Source:
    Samsung
    Title:

    Samsung Bioepis Receives European Commission Approval for AYBINTIO® (Bevacizumab)

    Published date:
    08/21/2020
    Excerpt:
    Samsung Bioepis (CEO: Han-Seung Ko) from the European Commission (EC) It was announced on the 21st that it has obtained the final marketing approval for'AYBINTIO ® , Avastin biosimilar, project name SB8, ingredient name bevacizumab' in Europe.
    Evidence Level:
    Sensitive: A1 - Approval
    New
    Source:
    European Medicines Agency
    Excerpt:
    Aybintio, in combination with topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum-resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other VEGF inhibitors or VEGF receptor targeted agents...
    Secondary therapy:
    pegylated liposomal doxorubicin; topotecan